Treatment Effects of Low-Dose Theophylline Combined With an Inhaled Corticosteroid in COPD

Ford, Paul; Durham, Andrew; Russell, Richard; Gordon, Fabiana; Adcock, Ian M.; Barnes, Peter J.

doi:10.1378/chest.09-2363

Cited by 162 publications

(108 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early on, it was recognised experimentally that xanthines could exhibit anti-inflammatory activity in the lung, additional to their bronchodilator activity [29], which has now been confirmed clinically by a number of laboratories in patients with asthma [30][31][32][33][34] or COPD [35,36]. Such observations demonstrated that it was possible to have both bronchodilator and anti-inflammatory activity in a single molecule.…”

Section: Bifunctional Bronchodilator/anti-inflammatory Drugsmentioning

confidence: 99%

Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease

Page

Cazzola

2014

Eur Respir J

View full text Add to dashboard Cite

Over the last decade, there has been a steady increase in the use of fixed-dose combinations of drugs for the treatment of a range of diseases, including hypertension, cancer, AIDS, tuberculosis and other infectious diseases. It is now evident that patients with asthma or chronic obstructive pulmonary disease (COPD) can also benefit from the use of fixed-dose combinations, including combinations of a long-acting b 2 -agonist and an inhaled corticosteroid, and combinations of long-acting b 2 -agonists and long-acting muscarinic receptor antagonists. In fact, there are now a number of ''triple-inhaler'' fixed-dose combinations under development, with the first such triple combination having been approved in India. This use of combinations containing drugs with complementary pharmacological actions in the treatment of patients with asthma or COPD has also led to the discovery and development of drugs having two different primary pharmacological actions in the same molecule, which we have called ''bifunctional drugs''. In this review, we discuss the state of the art of these new bifunctional drugs as novel treatments for asthma and COPD that can be categorised as bifunctional bronchodilators, bifunctional bronchodilator/antiinflammatory drugs and bifunctional anti-inflammatory drugs. @ERSpublications Bifunctional drugs offer an exciting new approach to the treatment of asthma and COPD

show abstract

Section: Bifunctional Bronchodilator/anti-inflammatory Drugsmentioning

confidence: 99%

Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease

Page

Cazzola

2014

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…Düşük doz teofilinin HADC aktivitesini arttırarak steroidlerin antiinflamatuvar etkilerini düzenlediği gösterilmiştir (26). Ford ve arkadaşları tarafından yapılan bir çalışmada teofilin ve inhale steroid kombinasyonunun KOAH'lı hastalarda inflamasyonu azaltabileceği görülmüştür (27). Curcumin (zerdeçal), daha çok köri sosunda kullanılan bir polifenoldür.…”

Section: Koah'ta Epigenetik Tedavi Yaklaşımlarıunclassified

Epigenetic and current treatment approaches in chronic obstructive pulmonary disease

Duru

2016

Tuberk Toraks

View full text Add to dashboard Cite

SUMMARY Epigenetic and current treatment approaches in chronic obstructive pulmonary disease Epigenetics mechanisms such as DNA methylation, histone acetylation and non-coding RNAs may play are a role in the pathogenesis of chronic obstructive pulmonary disease (COPD). Researchs with regard epigenetic in COPD can shed light on pathogenes and may be relevant in the development of novel targeted therapies. The aim of this article is to review epigenetic mechanisms new treatments approaches in COPD.

show abstract

“…Recently, FORD et al [61] randomly allocated 30 patients to treatment by either: 1) oral placebo + inhaled placebo followed by oral low-dose theophylline (250 mg b.i.d.) + inhaled placebo (4 weeks each, separated by a 2-week wash-out period), or 2) oral placebo + inhaled fluticasone (500 mg b.i.d.)…”

Section: Copd and Inflammation: New Data For New Treatmentsmentioning

confidence: 99%

Beyond corticosteroids: future prospects in the management of inflammation in COPD

Roche¹,

Marthan²,

Berger³

et al. 2011

Eur Respir Rev

View full text Add to dashboard Cite

Inflammation plays a central role in the pathophysiology of chronic obstructive pulmonary disease (COPD). Exposure to cigarette smoke induces the recruitment of inflammatory cells in the airways and stimulates innate and adaptive immune mechanisms. Airway inflammation is involved in increased bronchial wall thickness, increased bronchial smooth muscle tone, mucus hypersecretion and loss of parenchymal elastic structures. Oxidative stress impairs tissue integrity, accelerates lung ageing and reduces the efficacy of corticosteroids by decreasing levels of histone deacetylase-2. Protease-antiprotease imbalance impairs tissues and is involved in inflammatory processes. Inflammation is also present in the pulmonary artery wall and at the systemic level in COPD patients, and may be involved in COPD-associated comorbidities.Proximal airways inflammation contributes to symptoms of chronic bronchitis while distal and parenchymal inflammation relates to airflow obstruction, emphysema and hyperinflation. Basal levels of airways and systemic inflammation are increased in frequent exacerbators.Inhaled corticosteroids are much less effective in COPD than in asthma, which relates to the intrinsically poor reversibility of COPD-related airflow obstruction and to molecular mechanisms of resistance relating to oxidative stress. Ongoing research aims at developing new drugs targeting more intimately COPD-specific mechanisms of inflammation, hypersecretion and tissue destruction and repair. Among new anti-inflammatory agents, phosphodiesterase-4 inhibitors have been the first to emerge.

show abstract

Treatment Effects of Low-Dose Theophylline Combined With an Inhaled Corticosteroid in COPD

Cited by 162 publications

References 29 publications

Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease

Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease

Epigenetic and current treatment approaches in chronic obstructive pulmonary disease

Beyond corticosteroids: future prospects in the management of inflammation in COPD

Contact Info

Product

Resources

About